Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by SABBOBCATon Dec 01, 2022 10:26am
208 Views
Post# 35142854

Finishing on a strong note

Finishing on a strong noteCongrats to TH management for finishing the fiscal year on a strong note.

On the financial front, the share price is trading up 18% vs the 52 week low (let's ignore the fact it is down 34% from the 52 week high and hit fresh multi year lows). You got two new Analysts to initiate coverage with days to spare in the year so you can tick that box on the corp score card and get some cheap strike on your annual options. 

On the research front, you successfully moved into phase 1b and delivered some strong wording to investors... Only to leave them high and dry on updates and have them questioning if there is an enrolment issue? Oh and let's not forget the whole trial is running 6-12 months behind schedule. But not to worry, management is scheduled to talk at conferences in the coming months and will definitely have new exciting information (and not the same old regurgitated story every like in the past)... we "believe" you. 

In all seriousness though, the debt deal this year was a nice touch. I hope it can give enough runway to stave off another OO in the coming months. I really thought this holiday season was going to be a joyous one for TH shareholders, but yet again we are kicking dust down at these levels. If the broader market softens further, I fear that the opportunity cost of continuing to hold TH will be to great vs rotating into beta. We have already forgone recent bullish years in favor of compounded losses. When will this end? When will we finally see results from three years of NASH talk and maybe the promised YE update on TH1902? Will Paul be a man of his word? 
<< Previous
Bullboard Posts
Next >>